CRISPR Therapeutics Management
Management criteria checks 3/4
CRISPR Therapeutics' CEO is Sam Kulkarni, appointed in Dec 2017, has a tenure of 6.33 years. total yearly compensation is $12.32M, comprised of 5.9% salary and 94.1% bonuses, including company stock and options. directly owns 0.48% of the company’s shares, worth $22.72M. The average tenure of the management team and the board of directors is 5.4 years and 4.8 years respectively.
Key information
Sam Kulkarni
Chief executive officer
US$12.3m
Total compensation
| CEO salary percentage | 5.9% |
| CEO tenure | 6.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 5.4yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16
Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M
Aug 08Crispr Therapeutics' Continued Progress Warrants A Buy
Jul 25Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long Term
Jun 23Crispr Therapeutics: Progress, Risk, And Reward
Apr 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$12m | US$725k | -US$154m |
| Sep 30 2023 | n/a | n/a | -US$354m |
| Jun 30 2023 | n/a | n/a | -US$416m |
| Mar 31 2023 | n/a | n/a | -US$524m |
| Dec 31 2022 | US$21m | US$700k | -US$650m |
| Sep 30 2022 | n/a | n/a | -US$681m |
| Jun 30 2022 | n/a | n/a | -US$633m |
| Mar 31 2022 | n/a | n/a | US$312m |
| Dec 31 2021 | US$17m | US$670k | US$378m |
| Sep 30 2021 | n/a | n/a | US$412m |
| Jun 30 2021 | n/a | n/a | US$447m |
| Mar 31 2021 | n/a | n/a | -US$392m |
| Dec 31 2020 | US$9m | US$625k | -US$349m |
| Sep 30 2020 | n/a | n/a | -US$211m |
| Jun 30 2020 | n/a | n/a | US$20m |
| Mar 31 2020 | n/a | n/a | US$46m |
| Dec 31 2019 | US$16m | US$550k | US$67m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$200m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$10m | US$518k | -US$165m |
| Sep 30 2018 | n/a | n/a | -US$117m |
| Jun 30 2018 | n/a | n/a | -US$91m |
| Mar 31 2018 | n/a | n/a | -US$75m |
| Dec 31 2017 | US$7m | US$405k | -US$68m |
Compensation vs Market: Sam's total compensation ($USD12.32M) is above average for companies of similar size in the US market ($USD6.66M).
Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.
CEO
Sam Kulkarni (45 yo)
6.3yrs
Tenure
US$12,322,196
Compensation
Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as an Independent Non-Executive Director of Centessa Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 6.3yrs | US$12.32m | 0.48% $ 22.7m | |
| Chief Financial Officer | 1.1yrs | US$5.91m | 0.012% $ 556.6k | |
| General Counsel & Secretary | 6.9yrs | US$3.51m | 0.072% $ 3.4m | |
| Founder | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Head of Technical Operations | 4.5yrs | no data | no data | |
| Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
| Head of Human Resources | no data | no data | no data |
5.4yrs
Average Tenure
48yo
Average Age
Experienced Management: CRSP's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 5.8yrs | US$12.32m | 0.48% $ 22.7m | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Lead Independent Director | 3.8yrs | US$552.56k | 0.0024% $ 111.5k | |
| Independent Director | 9yrs | US$545.06k | 0.00032% $ 15.1k | |
| Independent Director | 4.8yrs | US$532.56k | 0% $ 0 | |
| Independent Director | 9yrs | US$542.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$555.06k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$536.24k | 0% $ 0 |
4.8yrs
Average Tenure
57yo
Average Age
Experienced Board: CRSP's board of directors are considered experienced (4.8 years average tenure).